Since 2017, four targeted therapies have been approved for treatment of AML: the FLT3 inhibitors midostaurin [10, 11] and gilteritinib [12] for newly diagnosed and relapsed/refractory patients, respectively, the IDH1 inhibitor ivosidenib [13, 14, 15] for newly diagnosed and relapsed/refractory patients, and the IDH2 inhibitor enasidenib [16] for relapsed/refractory patients. This evidence concerns the gene IDH2 and acute myeloid leukemia.